Dataset Information

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

ABSTRACT: Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01-15.97) in 268 incident cases of BCL (including multiple myeloma [MM]) and matched controls. Linear mixed models and partial least square analyses were used to analyze the association between levels of immune marker and the incidence of BCL and its main histological subtypes and to investigate potential biomarkers predictive of the time to diagnosis. Linear mixed model analyses identified associations linking lower levels of fibroblast growth factor-2 (FGF-2 p?=?7.2 × 10-4 ) and transforming growth factor alpha (TGF-?, p?=?6.5 × 10-5 ) and BCL incidence. Analyses stratified by histological subtypes identified inverse associations for MM subtype including FGF-2 (p?=?7.8 × 10-7 ), TGF-? (p?=?4.08 × 10-5 ), fractalkine (p?=?1.12 × 10-3 ), monocyte chemotactic protein-3 (p?=?1.36 × 10-4 ), macrophage inflammatory protein 1-alpha (p?=?4.6 × 10-4 ) and vascular endothelial growth factor (p?=?4.23 × 10-5 ). Our results also provided marginal support for already reported associations between chemokines and diffuse large BCL (DLBCL) and cytokines and chronic lymphocytic leukemia (CLL). Case-only analyses showed that Granulocyte-macrophage colony stimulating factor levels were consistently higher closer to diagnosis, which provides further evidence of its role in tumor progression. In conclusion, our study suggests a role of growth-factors in the incidence of MM and of chemokine and cytokine regulation in DLBCL and CLL.

SUBMITTER: Vermeulen R

PROVIDER: S-EPMC6100111 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

Vermeulen Roel R Saberi Hosnijeh Fatemeh F Bodinier Barbara B Portengen Lützen L Liquet Benoît B Garrido-Manriquez Javiera J Lokhorst Henk H Bergdahl Ingvar A IA Kyrtopoulos Soterios A SA Johansson Ann-Sofie AS Georgiadis Panagiotis P Melin Beatrice B Palli Domenico D Krogh Vittorio V Panico Salvatore S Sacerdote Carlotta C Tumino Rosario R Vineis Paolo P Castagné Raphaële R Chadeau-Hyam Marc M Botsivali Maria M Chatziioannou Aristotelis A Valavanis Ioannis I Kleinjans Jos C S JCS de Kok Theo M C M TMCM Keun Hector C HC Athersuch Toby J TJ Kelly Rachel R Lenner Per P Hallmans Goran G Stephanou Euripides G EG Myridakis Antonis A Kogevinas Manolis M Fazzo Lucia L De Santis Marco M Comba Pietro P Bendinelli Benedetta B Kiviranta Hannu H Rantakokko Panu P Airaksinen Riikka R Ruokojarvi Paivi P Gilthorpe Mark M Fleming Sarah S Fleming Thomas T Tu Yu-Kang YK Lundh Thomas T Chien Kuo-Liong KL Chen Wei J WJ Lee Wen-Chung WC Kate Hsiao Chuhsing C Kuo Po-Hsiu PH Hung Hung H Liao Shu-Fen SF

International journal of cancer 20180426 6

Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01-15.97) in 268 incident cases of BCL (in ...[more]

PMID: 29667176

Similar Datasets

Project description:A marked increase in leukemia risks was the first and most striking late effect of radiation exposure seen among the Hiroshima and Nagasaki atomic bomb survivors. This article presents analyses of radiation effects on leukemia, lymphoma and multiple myeloma incidence in the Life Span Study cohort of atomic bomb survivors updated 14 years since the last comprehensive report on these malignancies. These analyses make use of tumor- and leukemia-registry based incidence data on 113,011 cohort members with 3.6 million person-years of follow-up from late 1950 through the end of 2001. In addition to a detailed analysis of the excess risk for all leukemias other than chronic lymphocytic leukemia or adult T-cell leukemia (neither of which appear to be radiation-related), we present results for the major hematopoietic malignancy types: acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, adult T-cell leukemia, Hodgkin and non-Hodgkin lymphoma and multiple myeloma. Poisson regression methods were used to characterize the shape of the radiation dose-response relationship and, to the extent the data allowed, to investigate variation in the excess risks with gender, attained age, exposure age and time since exposure. In contrast to the previous report that focused on describing excess absolute rates, we considered both excess absolute rate (EAR) and excess relative risk (ERR) models and found that ERR models can often provide equivalent and sometimes more parsimonious descriptions of the excess risk than EAR models. The leukemia results indicated that there was a nonlinear dose response for leukemias other than chronic lymphocytic leukemia or adult T-cell leukemia, which varied markedly with time and age at exposure, with much of the evidence for this nonlinearity arising from the acute myeloid leukemia risks. Although the leukemia excess risks generally declined with attained age or time since exposure, there was evidence that the radiation-associated excess leukemia risks, especially for acute myeloid leukemia, had persisted throughout the follow-up period out to 55 years after the bombings. As in earlier analyses, there was a weak suggestion of a radiation dose response for non-Hodgkin lymphoma among men, with no indication of such an effect among women. There was no evidence of radiation-associated excess risks for either Hodgkin lymphoma or multiple myeloma.

Dataset Information

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

Publications

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure